Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Immunoglobulin Light-chain Amyloidosis 1Amyloid Neuropathies, Familial 1

Interventions

pembrolizumab 27Cisplatin 17Nivolumab 14Cyclophosphamide 14Carboplatin 13Radiation 12Paclitaxel 12Doxorubicin 11Radiotherapy 10Radiotherapy, Intensity-Modulated 9Cytarabine 9Vincristine 8Magnetic Resonance Spectroscopy 8Docetaxel 8Bevacizumab 8Radiosurgery 7Leucovorin 7Fluorouracil 7Etoposide 7Specimen Handling 6Prednisone 6Pemetrexed 6Irinotecan 6Injections 6Gemcitabine 6Dexamethasone 6venetoclax 5tislelizumab 5fludarabine 5enzalutamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene × 30 days × Clear all
NCT05184088 2026-06-02

CArdiag

Lantheus Biosciences Ltd.

Phase 3 Completed
244 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloid Neuropathies, Familial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡